Brought to you by 
Sanofi gets exclusive global rights to MannKind's newly approved Afrezza diabetes treatment; later terminated
25 Jan 2016
Executive Summary
Sanofi licensed exclusive worldwide rights to develop and sell drug delivery firm MannKind Corp.’s Afrezza (insulin) inhalation powder. The drug-device product was approved in June for adults with Type I and II diabetes.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi gets exclusive global rights to MannKind's newly approved Afrezza diabetes treatment; later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice